- Jean-Pierre Garnier, CEO, noted a difficult year with over Â£1.5bn in lost sales to generics, yet managed to grow the business.
- Development of experimental obesity treatment '771 was discontinued due to disappointing clinical trial results.
- 2005 is deemed an important year for research and development pipeline progress.
